NYSE · NVS
Novartis AG
$161.10+$5.02 (+3.22%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
Loading market information…
NASDAQ · REGN · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Regeneron Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Regeneron Pharmaceuticals, Inc.’s forward annual dividend is $3.76 per share, paid quarterly. The forward yield is 0.46% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Regeneron Pharmaceuticals, Inc.’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of $16.42. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Regeneron Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Apr 29, 2025 | $8.22-4.64% vs estimate | $3.03B-6.75% vs estimate |
|---|
| Q4 2024 | Feb 4, 2025 | $12.07+7.67% vs estimate | $3.79B+1.25% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | $12.46+6.59% vs estimate | $3.72B+1.25% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
49 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 19 contributors · Median target $855.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$161.10+$5.02 (+3.22%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
$174.40+$4.89 (+2.88%)
AstraZeneca PLC’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$165.61+$6.41 (+4.03%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$249.65+$5.60 (+2.29%)
Biogen Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
$56.49-$0.80 (-1.4%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 5.8% below the high.
HK$81.50-HK$0.10 (-0.12%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.68% below the high.
CN¥94.21+CN¥0.59 (+0.63%)
RemeGen Co. Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 40.3% below the high.
